The present invention relates to an implant comprising: -a core material comprising polydimethylsiloxane or at least one hydrogel polymer

TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention norgestimate is s...

597239 Disclosed herein is a pharmaceutical composition to be administered in a single dose, characterized in that it contains: 50-900 ?g levonorgestrel, 1-30 mg dienogest, 60-900 ?g desogestrel, 30-750 ?g gestodene, 1.5-75 mg chlormadinone acetate (CMA), 180-3700 ?g norgestimate (NGM), 1-15 mg cyproterone acetate (CPA), 2-30 mg drospirenone (DRSP), 30-450 mgdydrogesterone, 2-30 mg ethynodiol, 2-30 mg lynestrenol, 10-150 mg medrogestone, 10-150 mg medroxyprogesterone acetate (MPA), 0.5-8 mg nore...

TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention norgestimate is s...

Disclosed is the use of a progesterone selected from natural progesterone, 17-alphahydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethindrone enanthate, desogestrel, levonorgestrel, lynestrenol, ethynodiol diacetate, norgestrel, norgestimate, norethynodrel, gestodene, drospirenone, trimegestone, levodesogestrel, gestodyne, nesterone and etonogestrel, in the manufacture of a medicament for treating or preventing the onset of preterm labour and s...

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer

TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond.The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention norgestimate is sh...

The present invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen. The progestogen is levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, trimegestone, dienogest, precursors thereof and mixtures thereof. The kit comprises an amount of progestogen equivalent to 30-500 mg of levonorgestrel, 1-40 mg of ethinyl estradiol and 02-100 mg dehydroepiandrosterone.